Don’t miss your opportunity to be a part of this event, now a highly anticipated Campbell tradition, a decade in the making! More information at: library.campbell.edu/symposium2020
This project offers an exploration of a new line of diagnostic for prostate cancer. It is based on the aberrant expression of tNASP protein in prostate cancer cells. We examined the level of anti-tNASP antibodies in the sera of patients diagnosed with prostate cancer. Combined analysis of anti-tNASP and PSA tests demonstrated that 18.18% of PC patients with PSA higher than 4 ng/mL had a low level of anti tNASP antibody (false positive PSA, supported by negative biopsy); 9.1% of PC patients with PSA lower than 4 ng/mL had high levels of anti-tNASP antibodies (false negative PSA, proved histologically).
